^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
12/21/2021
Excerpt:
Esophageal and Esophagogastric Junction Cancers...Dostarlimab-gxly...for MSI-H or dMMR tumors
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Solid Tumor)
New
Excerpt:
JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced...solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

Published date:
01/11/2021
Excerpt:
Of the 106 pts, 99 (93.4%) had GI tumors. Confirmed ORR in dMMR pts was 38.7% (95% CI: 29.4, 48.6), with a complete response rate of 7.5%. ORR was consistent across tumor type (Table). Dostarlimab demonstrated durable antitumor activity in a cohort of dMMR solid tumor pts, the majority of whom had GI cancers.
Trial ID: